Faculty of Medicine, University of Tripoli, Tripoli, Libya.
Alhadba Alkhadra Hospital, Tripoli, Libya.
Travel Med Infect Dis. 2021 Jul-Aug;42:102064. doi: 10.1016/j.tmaid.2021.102064. Epub 2021 Apr 18.
The first case of the novel coronavirus disease 2019 (COVID-19) in Libya was diagnosed in March 2020. We aimed to determine the epidemiological, clinical, and laboratory characteristics of COVID-19 in Libya.
In this retrospective descriptive study, we analyzed the demographics, initial clinical presentation, history, comorbidities, laboratory findings, complications, and outcomes of hospitalized patients with COVID-19 at several centers in the Western part of Libya between March 24, 2020, and December 3, 2020.
The study included 811 (67.2%) men and 396 (32.8%) women. The median (interquartile range [IQR]) age was 56 (40-64). A total of 173 (14.3%) patients developed respiratory distress syndrome, while 70 (5.8%) developed circulatory shock and hypotension; 190 (15.7%) were admitted to the intensive care unit. Acute cardiac injury occurred in 27 (2.2%) patients, and 45 (3.7%) developed arrhythmia. Acute kidney injury occurred in 44 (3.6%) patients. Of the patients admitted during the study period, 149 (12.3%) died. The predominant comorbidities ordered in a descending manner were as follows; diabetes mellitus, presented 490 (40.6%), hypertension in 414 (34.3%), chronic kidney disease in 114 (9.4%), and lung diseases in 103 (8.5%). The total white blood cell, neutrophil; monocyte; D-dimer; creatinine kinase; creatine kinase-MB; creatinine; total bilirubin; alanine and aspartate aminotransferase; and hypersensitive troponin were increased among non-survivors, whereas lymphocyte and platelet counts were decreased among non-survivors.
This is the first report of the clinical presentations and laboratory findings in patients hospitalized with COVID-19 in Libya. Libyan authorities must implement several restrictions to control the pandemic. However, incoming international travelers pose a challenge to the local authorities, especially with the recent discovery of new variants.
2019 年新型冠状病毒病（COVID-19）在利比亚的首例病例于 2020 年 3 月确诊。我们旨在确定 COVID-19 在利比亚的流行病学、临床和实验室特征。
在这项回顾性描述性研究中，我们分析了 2020 年 3 月 24 日至 12 月 3 日期间利比亚西部地区几家中心住院 COVID-19 患者的人口统计学、初始临床表现、病史、合并症、实验室检查结果、并发症和结局。
该研究纳入 811 例（67.2%）男性和 396 例（32.8%）女性。中位（四分位距[IQR]）年龄为 56（40-64）岁。共有 173 例（14.3%）患者发生呼吸窘迫综合征，70 例（5.8%）发生循环休克和低血压；190 例（15.7%）患者入住重症监护病房。27 例（2.2%）患者发生急性心脏损伤，45 例（3.7%）发生心律失常。44 例（3.6%）患者发生急性肾损伤。在研究期间住院的患者中，149 例（12.3%）死亡。按降序排列，最常见的合并症如下：糖尿病，490 例（40.6%）；高血压，414 例（34.3%）；慢性肾脏病，114 例（9.4%）；肺部疾病，103 例（8.5%）。非幸存者的总白细胞、中性粒细胞、单核细胞、D-二聚体、肌酸激酶、肌酸激酶同工酶、肌酐、总胆红素、丙氨酸转氨酶和天冬氨酸转氨酶升高，而非幸存者的淋巴细胞和血小板计数降低。
这是利比亚首例 COVID-19 住院患者的临床表现和实验室检查结果报告。利比亚当局必须实施多项限制措施来控制疫情。然而，入境国际旅客对当地当局构成挑战，特别是最近发现了新的变异株。
